Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Open accessThe DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index.
Abstract
Colorectal cancer (CRC) is a predominant malignancy worldwide, being the fourth most common cause of mortality and morbidity. The CRC incidence in adolescents, young adults, and adult populations is increasing every year. In the pathogenesis of CRC, various factors are involved including diet, sedentary life, smoking, excessive alcohol consumption, obesity, gut microbiota, diabetes, and genetic mutations. The CRC tumor microenvironment (TME) involves the complex cooperation between tumoral cells with stroma, immune, and endothelial cells. Cytokines and several growth factors (GFs) will sustain CRC cell proliferation, survival, motility, and invasion. Epidermal growth factor receptor (EGFR), Insulin-like growth factor -1 receptor (IGF-1R), and Vascular Endothelial Growth Factor -A (VEGF-A) are overexpressed in various human cancers including CRC. The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) and all the three major subfamilies of the mitogen-activated protein kinase (MAPK) signaling pathways may be activated by GFs and will further play key roles in CRC development. The main aim of this review is to present the CRC incidence, risk factors, pathogenesis, and the impact of GFs during its development. Moreover, the article describes the relationship between EGF, IGF, VEGF, GFs inhibitors, PI3K/AKT/mTOR-MAPK signaling pathways, and CRC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Increased levels of cytokines and growth factors in the TME can activate cell proliferation and survival signaling pathways in CRC cells (e.g., MAPK and PI3K/AKT) [84].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Lin, X., Wang, S., Sun, M., Zhang, C., Wei, C., Yang, C., Dou, R., Liu, Q., & Xiong, B. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0708-7 · Cited by 207
RetractedZhang, D., Qiu, X., Li, J., Zheng, S., Li, L., & Zhao, H. (2018) · Cell Cycle · doi:10.1080/15384101.2018.1556064 · Cited by 72
RetractedBrenner, H., Kloor, M., & Pox, C. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61649-9 · Cited by 2,762
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Colorectal cancer statistics, 2014
Siegel, R., DeSantis, C., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21220 · Cited by 2,562
Pathological roles of MAPK signaling pathways in human diseases
Kim, E. K., & Choi, E.-J. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.12.009 · Cited by 2,472
Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. H., & Watanabe, T. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.65 · Cited by 1,563
Role of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
The MAPK signalling pathways and colorectal cancer
Fang, J. Y., & Richardson, B. C. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70168-6 · Cited by 1,185
Microsatellite Instability in Colorectal Cancer-the Stable Evidence
Vilar, E., & Gruber, S. B. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.237 · Cited by 1,063
Cited by
Items 201–300 of 436
Tacrolimus modulates the PI3K AKT mTOR pathway in retinal epithelial cells under inflammatory stress
Kiełbasińska, A., Grabarek, B. O., Janiszewska-Bil, D., Machaj, M., Lelek, Z., Lyssek-Boroń, A., Koss, M. J., Waszak, J., & Krysik, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-20650-1 · Cited by 5
“Therefore, modulation of this pathway could represent a key therapeutic strategy in halting or reversing the cellular events that drive PVR progression 15 .”
Sharma, A., Suvedi, D., Kumar, A., Khanal, S., Verma, R., Kumar, D., Kumar, D., Tapwal, A., Kumar, V., & Peter, L. (2025) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-025-04687-y · Cited by 6
Dutta, S., Rajesh, R., Matada, G. S. P., Paik, A., Dasgupta, A., Pal, R., Kushal, J., & Pavani, G. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118538 · Cited by 5
Atia, G. A. N., Ali, M. A., Abdeen, A., Alghonemy, W. Y., Elsayed, A. Z., Shaban, E., Mohammed, N. A., Mohamed, M. E., Hetta, H. F., Abass, K. S., et al. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108140 · Cited by 7
Esmaeilpour, D., Ghavami, S., Zarrabi, A., Khosravi, A., Zarepour, A., Cordani, M., Klionsky, D. J., Hamblin, M. R., & Sillanpää, M. E. T. (2026) · Drug Discovery Today · doi:10.1016/j.drudis.2026.104633 · Cited by 5
Xu, M. Q., Tsunedomi, R., Kiyotani, K., Tomochika, S., Furuya, K., NAKAJIMA, M., MATSUI, H., Tokumitsu, Y., Shindo, Y., Yoshida, S., et al. (2023) · Anticancer Research · doi:10.21873/anticanres.16197 · Cited by 5
Islam, R., Hossain, M. S., Mock, P. Y., Leong, S. W., & Lam, K. W. (2023) · Medicinal Chemistry Research · doi:10.1007/s00044-023-03063-5 · Cited by 5
“The PI3K/Akt/mTOR pathway is one of the most altered signalling cascades in various types of cancer, including lung cancer [16], breast cancer [17], oesophagal cancer [18], hepatocellular carcinoma[19], prostate cancer [20] and colorectal cancer [21].”
BackgroundЗахарова, Г. С., Modestov, A., Pugacheva, P. A., Mekic, R., Savina, E. A., Guryanova, A., Rachkova, A. A., Yakushov, S., Alimov, A. A., Kulaeva, E. D., et al. (2023) · Cells · doi:10.3390/cells12091299 · Cited by 5
Dawoud, M. M., Salah, M., & Mohamed, A. S. E. D. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03041-6 · Cited by 7
“These pathways are among the tumorigenic pathways in CRC [31, 32].”
BackgroundHan, X., Liu, Y., Tian, H., & Ji, Y. (2023) · Aging · doi:10.18632/aging.205119 · Cited by 6
Chen, J., Wu, S., Shi, Z.-M., Qu, Y.-J., Ding, M.-R., & Hu, B. (2023) · Hereditas · doi:10.1186/s41065-023-00303-x · Cited by 5
“When triggered by varied stimuli, the MAPK pathway can con-trol the growth, differentiation, apoptosis, migration, and invasion of tumor cells [53].”
BackgroundMa, Z., Ma, Y., Feng, J., Xu, Z., Cheng, C., Qin, J., Li, S., Jiang, J., & Kong, R. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116915 · Cited by 5
Role of dietary nutrients and metabolism in colorectal cancer.
Ye, J., Bao, X., Wei, J., Zhang, Y., Liu, Y., & Xin, L. (2024) · PubMed Central · doi:10.6133/apjcn.202406_33(2).0002 · Cited by 8
Shojaeian, A., Barati, N., & Motavallihaghi, S. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947299692240801081928 · Cited by 5
Al‐Hawary, S. I. S., Altalbawy, F. M. A., Jasim, S. A., Renuka Jyothi, S., Jamal, A., Naiyer, M. M., Mahajan, S., Kalra, H., Jawad, M. A., & Zwamel, A. H. (2024) · Cell Biology International · doi:10.1002/cbin.12231 · Cited by 5
Mohamed, A. H., Aly, A. A., Alshammari, M. B., Ahmad, A., Balboul, B. A. A., Ghareeb, D. A., Abdelaziz, M. E., & El-Agroudy, E. J. (2024) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-024-03259-4 · Cited by 5
Liu, J., Luo, D., Chen, X., Liu, J., Chen, J., Shi, M., Dong, H., Xu, Y., Wang, X., Yu, Z., et al. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102199 · Cited by 5
The emerging role of fasting-mimicking diets in cancer treatment
Zhai, Y., Si, P., Liu, M., & Huang, L. J. (2023) · journal of nutritional oncology · doi:10.1097/jn9.0000000000000015 · Cited by 5
“[13] Therefore, an FMD would de-creaseIGF-1/mTORsignaling,therebyinhibitingtumordevelopment.”
Zhou, W., Li, H., Zhang, M., Han, J., Zhang, W., & Jin, T. (2025) · Molecular Genetics and Genomics · doi:10.1007/s00438-025-02246-6 · Cited by 5
“In 70% of CRC patients, the overexpression of phosphorylated AKT is associated with the inhibition of cell division and apoptosis, as well as abnormal expression of the tumor suppressor PTEN (Stefani et al. 2021).”
Spinosyn A and Its Derivative Inhibit Colorectal Cancer Cell Growth via the EGFR Pathway
Peng, K., Zou, Z., Li, J., Xie, Y., Ming, Z., Jiang, T., Luo, W., Hu, X., Nie, Y., Chen, L., et al. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00276 · Cited by 5
Medicinal Plant-rich Diet: A Potential Therapeutic Role in Colorectal Cancer
Tripathi, P. K., & Jain, C. K. (2023) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525722666230915103747 · Cited by 6
Taherkhani, A., Moradifar, G., Bayat, Z., Samadi, P., & Jamshidi, S. (2023) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2023.04.005 · Cited by 5
Zhao, H., Wu, Y., & Kim, S. M. (2025) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.24.274 · Cited by 4
“Human malignancies frequently exhibit active Akt/mTOR signaling, which is crucial for cell survival, growth, and proliferation [47].”
SARS-CoV-2 accessory proteins ORF3a and ORF6 alter the miRNome of human lung epithelial cells
Apoorva, Kumar, A., Chakrabarti, S. S., & Singh, S. K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10596-y · Cited by 4
Li, X., Li, X., Wang, J., Xue, M., Zhang, M., Shuai, J., Zhang, J., Ding, D., Wang, Y., Hou, S., et al. (2025) · Oncology Reports · doi:10.3892/or.2025.8949 · Cited by 5
“The Akt/mTOR signaling pathway is hyper‑activated in various types of cancer, including CRC (37).”
Chen, J.-S., Enwolo-Chibueze, C. G., Chinyama, H. A., Lai, C.-T., Ezeala, I. C., Huang, P.-Y., Wu, A. T. H., & Huang, Y.-J. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188780 · Cited by 4
“Current treatment options for colorectal cancer comprise surgery for localized tumors, radiation therapy, chemotherapy, targeted therapy, and immunotherapy [2,3].”
Ahmad, S., Qazi, S., Bano, N., Uddin, R., Gautam, P. K., & Raza, K. (2026) · PLoS ONE · doi:10.1371/journal.pone.0344028 · Cited by 4
“Additionally, CDK2 activity is modulated by upstream mitogenic signals through the Rb-E2F pathway, linking growth factor signalling to uncontrolled DNA synthesis in cancer cells [ 28,29,30].”
Ullah, A., Khan, B. M., Khan, N. U., Muntaha, S. T., Khan, S., Khan, A. U., Almutairi, M. H., & Ali, I. (2023) · Molecular Biology Reports · doi:10.1007/s11033-023-08943-y · Cited by 5
“Over the past two decades, scientists performed many studies to find the association of HER1 and HER2 gene polymorphism with CRC and its therapeutic role in the treatment of metastatic CRC [18].”
BackgroundWang, G., Guo, C., Pi, H., Wang, Y., Lin, S., Bi, K., Zhang, M., Wang, N., & Zhao, G. (2024) · Aging · doi:10.18632/aging.206075 · Cited by 4
Aytekin, A., Kadakal, H., Mıhçıoğlu, D., & Gurer, T. (2025) · BMC Medical Genomics · doi:10.1186/s12920-024-02080-6 · Cited by 5
The Effect of Astaxanthin on the Treatment of Neurological Diseases and Lesions
Moghadam, B. B., Shirian, S., & Mashaie, K. S. (2024) · The Neuroscience Journal of Shefaye Khatam · doi:10.61186/shefa.13.1.87 · Cited by 4
Role of Yin Yang 1 (YY1) on microenvironment, signaling pathways, and epigenetics in lung cancer
Kumari, S., Ponamgi, S. P. D., Chelikani, P., Srilatha, M., Nagaraju, G. P., & Peela, S. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189359 · Cited by 5
Downregulation of Ezrin Suppresses Migration Potential in Cervical Cancer Cells
Hałas‐Wiśniewska, M., Arendt, W., Grzanka, A., & Izdebska, M. (2024) · Pharmaceuticals · doi:10.3390/ph18010003 · Cited by 4
Al-Hussaniy, H. A., Oraibi, A. I., Al-Tameemi, Z. S., Alburghaif, A. H., Naji, M. A., & Naji, F. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096349198250407100724 · Cited by 4
Sommariva, S., Berra, S., Biddau, G., Caviglia, G., Benvenuto, F., & Piana, M. (2023) · Frontiers in Systems Biology · doi:10.3389/fsysb.2023.1207898 · Cited by 5
Hu, Q., Zheng, Q., Du, X., Yang, Z., Tian, Q., Liang, L., Zhao, X., Bai, H., Liu, Y., Zhao, M., et al. (2024) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2024.116960 · Cited by 4
In Vivo Sentinel Lymph Node Detection with Indocyanine Green in Colorectal Cancer.
Stăniloaie, D., Budin, C., Ilco, A., Vasile, D., Călinoiu, A. L., Rusu, A., Iancu, G., Ammar, T. A. R. A., Georgescu, C. F., Tănăsescu, M., et al. (2022) · PubMed · doi:10.26574/maedica.2022.17.2.264 · Cited by 5
Wu, J., Wang, M., Zhang, Y., Liu, G., & Xing, Y. (2024) · Functional & Integrative Genomics · doi:10.1007/s10142-024-01299-x · Cited by 3
Expression Pattern of PDE4B, PDE4D, and SFRP5 Markers in Colorectal Cancer
Bevanda, M., Kelam, N., Racetin, A., Filipović, N., Glibo, D. B., Bevanda, I., & Vukojević, K. (2024) · Medicina · doi:10.3390/medicina60081202 · Cited by 5
“PDE4D, on the other hand, can alter gene expression and impact the tumor microenvironment, thereby influencing various aspects of cancer biology, including the response to therapies [26].”
BackgroundDeng, M., Hu, G., Liang, F., Liao, Q., Ding, W., He, B., Ming, J., Huang, H., Liu, J., Kong, Z., et al. (2024) · Nano Materials Science · doi:10.1016/j.nanoms.2024.08.001 · Cited by 3
Huang, T., Chen, H., Pan, H., Wu, T., Ren, X., Qin, L., Yuan, K., & He, F. (2024) · PLoS ONE · doi:10.1371/journal.pone.0315534 · Cited by 4
Zhang, H., Zhou, B., Liu, J., Tang, B., Xie, Z., & Li, J. (2025) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2025.04.001 · Cited by 3
Emelyanova, A. G., Zolotovskaia, M., Poddubskaya, E. V., Modestov, A., Prassolov, V., Kuzmin, D., & Buzdin, A. A. (2025) · Acta Naturae · doi:10.32607/actanaturae.27497 · Cited by 3
Suwal, N., Thapa, R., Bashyal, S., Sugandhi, V. V., Subedi, S., Panth, N., Amorim, N. M. L., Choi, J. P., Gupta, M., Idrees, S., et al. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.106887 · Cited by 3
Liang, J., Li, A., Chen, J., Cao, N., Zhu, T., Ru, C., Zhou, S., Liang, Y., & Tang, X. (2025) · Cancer Medicine · doi:10.1002/cam4.71000 · Cited by 3
“Upon ligand binding, IGF1R activates downstream signaling pathways including the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathways, which are integral to cellular proliferation and survival [17, 18].”
Xu, C., Zhang, S., Sun, B., Yu, Z., & Liu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1639303 · Cited by 5
So, S. H. S., Jiang, W., Li, Y., Hold, G. L., Goodrick, K., Min, A., Bourke, M. J., El-Omar, E. M., Jiang, X., & Yim, H. C. H. (2025) · eGastroenterology · doi:10.1136/egastro-2025-100194 · Cited by 4
COMP promotes the progression of colorectal cancer by regulating epithelial mesenchymal transition
Huang, H., Wang, L., Gao, S., & Wang, H. (2025) · BMC Cancer · doi:10.1186/s12885-025-15000-3 · Cited by 3
“The PI3K-AKT pathway is essential for CRC development, playing a critical role in proliferation, metastasis, survival, and angiogenesis [25].”
Wu, L. H., Zhang, Z., Tian, D., Chen, K., Liang, J.-H., Yu, H., Wang, K., Chen, K., Wu, Y., & Yan, H. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110671 · Cited by 3
Cryptotanshinone targets tumor-immune-microbiome axis to suppress colorectal cancer
Yang, Z., Zhou, M., Luo, F., Feng, S., Tan, Y. J., Wang, Q., Cheng, Z., Tan, R., & Li, R. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1667500 · Cited by 3
Krishnamoorthy, S., Renu, K., & Veeraraghavan, V. P. (2026) · Cardiovascular Toxicology · doi:10.1007/s12012-026-10097-9 · Cited by 3
Chen, S., Shi, X., Liu, S. Q., Pei, P., Yang, K., & Hu, L. (2024) · Journal of intelligent medicine. · doi:10.1002/jim4.16 · Cited by 3
Luo, Y., Li, H., Fang, H., Gong, T., Zhao, Y., Cao, W., Yu, M., Wang, T., Lin, H., & Zhong, M. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf040 · Cited by 4
Yang, L., & Zhang, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-15389-8 · Cited by 3
“The role of FSTL3 in the pro-survival PI3K-Akt signaling pathway has not been characterized, and it warrants further exploration since PI3K-Akt is a pivotal pathway in anoikis resistance 40 and CRC development 57 .”
Wang, S., Peng, X., Ran, Y., Feng, R., Xia, Y., & Liu, Y. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05993-2 · Cited by 3
“…TGF-α triggers downstream sig - naling pathways such as phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) and mitogen-activated protein kinase/ extracellular signal-regulated kinase (MAPK/ERK), which regulate various cellular processes including proliferation, migration, and survival [20, 21].”
Landscape of N1 ‐methyladenosin ( m1A ) modification pattern in colorectal cancer
Jiang, C., Tian, Y., Xu, C., Zhang, H., & Gu, L. (2023) · Cancer Reports · doi:10.1002/cnr2.1965 · Cited by 6
Bilachi, R. S., Ananya, G., Kumar, C. H., Ramírez, D. C., & Gomez-Mejiba, S. (2024) · Microbial Pathogenesis · doi:10.1016/j.micpath.2024.106770 · Cited by 3
Nagamine, H., Yashiro, M., Mizutani, M., Sugimoto, A. K., Matsumoto, Y., Tani, Y., Sawa, K., Kaneda, H., Yamada, K., Watanabe, T., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0297397 · Cited by 4
pERK transition–induced directional mode switching promotes epithelial tumor cell migration
Yu, H.-L., Xiao, G., Gu, M., Zhang, L., Xia, M., Mo, S., Zhao, Y., & Wei, C. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318871121 · Cited by 3
“These include the activation of AKT and subsequent mTOR pathways through the PI3K/AKT/mTORC1 signaling ( 22 ), and the induction of the AMPK pathway through Ca 2+ /calmodulin - dependent kinase ( 23 ).”
Dabiri, M., Tehrani, M., Rafiei, A., & Valadan, R. (2024) · Protein Expression and Purification · doi:10.1016/j.pep.2024.106649 · Cited by 3
Zafar, A., Khalid, M., Alsaidan, O. A., & Mujtaba, M. A. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.155956 · Cited by 3
Research on the pathological mechanism of rectal adenocarcinoma based on DNA methylation
Pan, X., Yi, X., Lan, M., Su, X., Zhou, F. J., & Wu, W. (2023) · Medicine · doi:10.1097/md.0000000000032763 · Cited by 3
“We speculate that increased methylation of endothelial cells leads to changes in the normal tissue microenvironment.[21] Development of adenoma and continued progression of adenoma to cancer driven by a continued increase in hypermethylation status, with progression to cancer status followed by a reduction in methylat…”
BackgroundNew Perspectives in Colorectal Cancers Treatment, the Role of MicroRNAs
Belova, V. A., Спирина, Л. В., Августинович, А. В., Afanas'ev, S. G., Volkov, M. Y., Игоревич, А. Д., Volkov, A., & Klyushina, T. S. (2024) · Current Drug Targets · doi:10.2174/0113894501304351240703113651 · Cited by 2
Snake venom in conjugation with silica nanoparticles: an emerging cancer therapy
Azam, D., Arshad, N., Khalid, M., Hassan, S., Anjum, S., Sharif, E., & Ibrahim, W. N. (2025) · ONCOLOGIE · doi:10.1515/oncologie-2025-0056 · Cited by 2
“This is a critical pathway in targeting cancer treatment [137].”
Ren, C., Qin, Y., Cao, D., Ren, X., Zhao, H., Han, J., & Du, G. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70353 · Cited by 2
“Nevertheless, resistance to these agents has been observed, driven by receptor mutations and the activation of alternative signaling pathways [3].”
Pasdar, A., Rahmani, F., & Amerizadeh, F. (2025) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2025.26.7.2511 · Cited by 3
“Recent studies indicate that NRAS mutations can drive therapy resistance through MAPK pathway hyperactivation, paralleling findings in colorectal cancer [29].”
Targeting PI3K/AKT/mTOR signaling: A promising therapeutic approach for colorectal cancer
Qu, Z., Pen, X., Lu, X., & Luo, S. (2025) · Eurasian Journal of Medicine and Oncology · doi:10.36922/ejmo025190175 · Cited by 2
Khan, M. N., Tian, K., Gordon, J., Li, F., & Ding, S. (2025) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2025.069408 · Cited by 2
“Mechanistically, our results indicate that the enhanced anti-tumor effects observed with gefitinib + G31P treatment are primarily due to inhibition of PI3K/AKT and MAPK/ERK pathways, which are central to EGFR-driven tumor growth [35].”
Wang, Z., Zhu, F., & Dai, L. (2025) · Journal of International Medical Research · doi:10.1177/03000605251392443 · Cited by 2
“13 Additionally, hypertriglyceridemia may activate the TLR4/NF-j B inflammatory signaling axis through the release of free fatty acids, resulting in the formation of a chronic inflammatory microenvironment in the intestine.”
Król-Jatręga, K., Mitka-Krysiak, E., Boroń, K., Ossowski, P., Zmarzły, N., Ordon, P., Kulej, W., Sirek, T., Sirek, A., Boroń, D., et al. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411831 · Cited by 2
“This highly conserved cascade integrates external signals through a series of kinases—including ERK1/2, JNK, and p38—that regulate key cellular processes such as proliferation, differentiation, survival, and inflammation [20,21].”
Wang, W., Jia, W., Du, Y., Zhao, D., & Chang, S. (2026) · Scientific Reports · doi:10.1038/s41598-026-36478-2 · Cited by 2
“Previous studies have demonstrated that Wnt hyperactivation disrupts intestinal stem cell differentiation to initiate tumorigenesis 35 , MAPK signaling, involving ERK1/2, JNK, and p38 families 36 , drives cancer progression 37 , and TGF-β enhances tumor cell survival, invasion, and metastasis 38 .”
Uddin, M. B., Shipon, M. N. H., Suma, R., Rahman, A., Alkhathami, A. G., Mia, E., Khalipha, A. B. R., Akter, K., & Hasan, M. S. A. (2026) · Phytochemical Analysis · doi:10.1002/pca.70052 · Cited by 2
“Cancer cell survival is often sustained by aberrant activation of signaling pathways such as PI3K/Akt/mTOR, MAPK/ERK, and NF-κB, which promote proliferation, inhibit apoptosis, and confer resistance to therapy [60].”
Święch, M., Lorenc-Góra, J., Muc‐Wierzgoń, M., Świętochowska, E., Kowalczyk, P., Czuba, Z. P., & Waniczek, D. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27052156 · Cited by 3
Yousefipour, K., Rohani, S. S. R., Hosseini, S. M. M., Kafilzadeh, K., Alavi, N. S., & Firouzabadi, N. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04351-x · Cited by 2
“Some in vitro and preclinical studies are underway to use MAPK inhibitors in combination therapies [193].”
Koustas, E., Trifylli, E.-M., Oraiopoulos, V., Karamouzis, M. V., & Sarantis, P. (2026) · Genes · doi:10.3390/genes17060674 · Cited by 3
“Moreover, activation of well-known signaling pathways such as RAS/RAF/MEK/ERK and PI3K/AKT/mTOR contributes to tumor progression and immune evasion by promoting tumor cell proliferation, reducing neoantigen presentation, and augmenting an immunosuppressive TME [20].”
Keskin, İ., Sahin, B., Bülbül, A., Çakır, M., Yavuz, M., Bülbül, M. V., & Demircan, T. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27135672 · Cited by 2
“Notably, the observed suppression of mTOR/AKT signaling provides a plausible mechanistic framework for these effects, as AKT/mTOR is a central pathway driving cell growth and survival in colon cancer and other malignancies [30–32].”
Christenson, E. S., Wala, J. A., Parkinson, R. M., Collins, N. B., Jakubowski, C. D., Lin, J., Qian, K., Lu, J. H., Wang, H., Ho, W. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72985-6 · Cited by 2
“In addition to PI3K/AKT signaling, CRC tumors often rely on the mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) signaling to achieve sustained cellular proliferation 34 .”
Aiyejuto, D., Luthria, A., Hui, T., & Shenoy, A. K. (2026) · Cancers · doi:10.3390/cancers18162569 · Cited by 2
“…Wnt/ β -catenin activation can stabilize RAS and enhance MAPK signaling in CRC [134], while ERK and PI3K/AKT pathways converge on shared downstream effectors [135,136], providing multiple redundant routes to sustain CCSC survival and therapeutic resistance even when single pathways are inhibited.”
Kolorektal Kanserde Rapamisin ve Vemurafenib’in Apoptotik Etkilerinin Karşılaştırılması
Nakkaş, H., Sancı, T. Ö., BEDİR, B. E. Ö., & Terzi, E. (2023) · Uludağ Üniversitesi Tıp Fakültesi Dergisi · doi:10.32708/uutfd.1376556 · Cited by 2
Yan, S., Zhao, J., Gao, P., Li, Z., Zhao, L., Liu, X., & Wang, P. (2024) · Diagnostic Pathology · doi:10.1186/s13000-024-01438-9 · Cited by 2
Biradar, M. S., Thapa, S., Shinde, S., Sarkate, A. P., & Padvi, K. S. (2024) · Springer eBooks · doi:10.1007/978-981-99-9462-5_18 · Cited by 3
Fan, Y., Wang, Q., Zhang, Y., Wang, Y., Li, W., Jiang, S., & Duan, J. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae045 · Cited by 3
Lee, J.-Y., Lee, Y., Park, J., Kang, H.-Y., Heo, Y. U., Kim, A., Kim, N., Roh, H., & Kim, D. (2025) · Aquaculture · doi:10.1016/j.aquaculture.2025.742267 · Cited by 2
Gharaee, N., Wegrzyn-Woltosz, J., Jiang, J., Akhade, V. S., Bridgers, J., Stubbins, R. J., Hiwase, D., Kutyna, M., Chan, O., Komrokji, R. S., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02537-2 · Cited by 2
Hakaman, H., Surya, F., Gerardine, G. E., Honggo, H., & Parikesit, A. A. (2025) · Berkala Penelitian Hayati · doi:10.23869/bphjbr.31.1.20256 · Cited by 2
Analysis of IGFL2 Gene Expression and Prognostic Value in Bladder Cancer Based On TCGA Database
Aizezi, X., Silafu, B., Ma, Y., Wang, Z., Li, J., & Huang, J. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14191 · Cited by 2
“PI3K–Akt and the MAPK pathways are among the best involved in the regulation of tumor cell proliferation, survival, migration, and invasion in several types of cancers [22–24].”
Bagrezaei, F., Kheirouri, S., & Alizadeh, M. (2025) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2025.30.3.250 · Cited by 2
“Studies have shown that mutagens in the -catenin, RAS-ERK, and PI3K/AKT pathways play essential roles in tumorigenesis (Jeong et al., 2018; Ryu et al., 2021; Stefani et al., 2021).”
Sahoo, R. K., Ansari, Z. A., Pradhan, S. K., & Biswal, B. K. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156243 · Cited by 2
Investigate the role of PIK3CA gene expression in colorectal polyp development
Imarah, A. A., Najm, R. A., Alnaji, H. A., Al-Hadraawy, S. K., Almulla, A. F., & Al-Gazali, H. R. (2023) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2023.2245992 · Cited by 2
“The severity of this type of polyps came from the ability to cumulate mutations associated with cell cycle control over years [1] and PIK3CA , one of these genes [9].”
BackgroundDR6 Augments Colorectal Cancer Cell Growth, Invasion, and Stemness by Activating AKT/NF-κB Pathway
Jia, J., Huang, Y., Chen, Q., Hou, J., Liu, Y., Xie, L., Li, X., & Yang, C. (2024) · Biochemical Genetics · doi:10.1007/s10528-024-10673-0 · Cited by 2
NOX4 promotes tumor progression through the MAPK-MEK1/2-ERK1/2 axis in colorectal cancer
Xu, Y.-J., Huo, Y., Zhao, Q., Liu, J., Tian, Y., Yang, L., & Zhang, Y. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i4.1421 · Cited by 1
Тимошкина, Н. Н., Gvaldin, D. Y., Eid, M., Alset, D., Petrusenko, N. A., Novikova, I. A., & Kit, O. I. (2024) · Human Gene · doi:10.1016/j.humgen.2024.201334 · Cited by 1
Wu, B., Zhang, W., Wang, X., Wang, Q.-M., Pang, Y.-J., & Kong, Y. (2025) · International Journal of Ophthalmology · doi:10.18240/ijo.2025.02.03 · Cited by 1
“At present, multiple scholars have found that drugs affect the expression of VEGF via the PI3K/Akt/mTOR pathway, thereby affecting the development or treatment in many diseases, such as coloretal cancer [20] , gastric cancer [21] , steoporotic fractures [22] , ischemic stroke [23] etc .”
CNPY3’s regulation of tumor microenvironment and its impact on colon cancer aggressiveness
Gao, X., Zhou, B., Feng, X., Ji, Z., Li, Q., & Liu, H. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01145-1 · Cited by 2
“Given its established role in oncogenic pathways (Stefani et al. 2021), it stands to reason that CNPY3 may also influence signaling pathways between tumor cells and the surrounding stromal cells (Wei et al. 2024a, b).”
Research Progress on PI3K/AKT/mTOR Signaling Pathway and Multidrug Resistance in Breast Cancer
陈, 鸿. (2025) · Hans Journal of Biomedicine · doi:10.12677/hjbm.2025.152039 · Cited by 1
Liu, Y., Huang, M., Tian, X., & Huang, X. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040267 · Cited by 2
“Overactivation of the MAPK pathway (usually caused by KRAS or BRAF mutations) is also involved in CRC progression by promoting angiogenesis, invasion, and metastasis [47].”
Xiong, Y., Xiong, W., Wang, Y., He, C., Zhan, Y., Pan, L., Luo, L., & Song, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-03712-2 · Cited by 2
“First, the clinical application of the ISs score requires broader clinical validation, particularly through multi-center, large-sample studies 30–32 .”
Seigner, J., Krier, J., Spähn, D., Sandforth, L., Nono, J. L., Łukowski, R., Birkenfeld, A. L., & Sancar, G. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102210 · Cited by 2
“While PI3K/AKT and RAS/RAF/MAPK pathways are canonical pathways for growth factor signaling [32,33], neither AKT or mTOR nor ERK inhibition prevented the antilipolytic role of the FGF1/PDE4D pathway indicating a novel signaling cascade regulating lipolysis via FGF1/PDE4D.”
Ciołczyk-Wierzbicka, D., Sikorska-Duplicka, M., Zarzycka, M., Zemanek, G., & Wierzbicki, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26167770 · Cited by 1
“One of the key pathways implicated in melanoma progression is the PI3K/AKT/mTOR signaling cascade, which plays a central role in regulating cell growth, proliferation, invasion, apoptosis, autophagy, and metabolic reprogramming [8–10].”
Zhao, C., Xiong, H., Zhu, L.-F., Adali, A., Yu, W., Tan, S., Wang, S., Zhao, C.-B.-W., Lin, Y., Wei, Z., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1615095 · Cited by 1
Metadata
- Authors
- Stefani, C., Miricescu, D., Stanescu-Spinu, I.-I., Nica, R. I., Greabu, M., Totan, A. R., & Jinga, M.
- Affiliations
- Department of Family Medicine and Clinical Base, ‘‘Dr. Carol Davila’ Central Military Emergency University Hospital, 051075 Bucharest, Romania
- Carol Davila University of Medicine and Pharmacy (RO)
- Department of Biochemistry, Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, 8 Eroii Sanitari Blvd, 050474 Bucharest, Romania
- Spitalul Universitar de Urgenţă Militar Central Dr. Carol Davila (RO)
- Corresponding author
- Miricescu, Daniela
- Greabu, Maria
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-09-23
- Volume
- 22
- Issue
- 19
- Pages
- 10260
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8508474
- OpenAlex
- W3200117713
- Cited by
- 402
- References
- 206
- Citations by year
- 2026: 69 · 2025: 134 · 2024: 103 · 2023: 68 · 2022: 26 · 2021: 2
- FWCI
- 5.21
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- colorectal cancer, growth factors, PI3K/AKT/mTOR pathway, MAPK signaling, tumor microenvironment, EGFR, IGF-1 receptor, VEGF-A, growth factor inhibitors, colorectal cancer risk factors, colorectal cancer pathogenesis, cell proliferation and invasion
- MeSH terms
- Animals, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Mitogen-Activated Protein Kinases, Intercellular Signaling Peptides and Proteins, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

